ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN PERIMENOPAUSAL WOMEN: THE IMPACT OF HORMONAL CHANGES ON SYMPTOM SEVERITY AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Authors:
- Nicole Aleksandra Ordyczyńska-MardyłaNONicole Aleksandra Ordyczyńska-Mardyła
- Anna ŁęCzyckaAŁAnna ŁęCzycka
- Kinga HaduchKHKinga Haduch
- Zuzanna MichalskaZMZuzanna Michalska
- Izabela Zuzanna StranzISIzabela Zuzanna Stranz
- Aleksandra StańczykASAleksandra Stańczyk
- Olga Helena ChorążyOCOlga Helena Chorąży
- Joanna StrzelczykJSJoanna Strzelczyk
- Iga SuchtaISIga Suchta
- Amelia KęDzioraAKAmelia KęDziora
Open Access
- 30 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Abstract
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is increasingly recognized as a lifelong condition; however, the impact of the menopausal transition on its symptomatic trajectory remains significantly under-researched. In females, ADHD is frequently masked by compensatory mechanisms until midlife, leading to diagnostic delays. This review examines the neurobiological and clinical intersection between fluctuating ovarian steroids and ADHD pathophysiology. Methods: A narrative synthesis of 20 selected scientific sources was conducted, incorporating neuroendocrinological reviews, clinical cohort studies, neuroimaging data, and qualitative research. Results: Evidence indicates a "double whammy" effect from the convergence of neurodevelopmental dopamine deficiency and perimenopausal estrogen withdrawal. 17β-estradiol acts as a critical neuromodulator of dopaminergic and serotonergic systems, exerting neuroprotective effects on the prefrontal cortex. Its decline during perimenopause unmasks previously latent ADHD symptoms, exacerbating executive dysfunction ("brain fog"), inattention, and emotional dysregulation. Women with hormone-related mood disorders such as PMDD exhibit heightened vulnerability. Additionally, "diagnostic overshadowing" frequently occurs, whereby ADHD symptoms are misattributed to menopausal depression or anxiety. The analysis highlights the efficacy of lisdexamfetamine in mitigating cognitive deficits in this demographic. Conclusions: The menopausal transition represents a period of significant clinical vulnerability for women with ADHD. Optimizing outcomes requires individualized, interdisciplinary strategies integrating stimulant pharmacotherapy with Hormone Replacement Therapy (HRT) and gender-sensitive psychoeducation. Future longitudinal research is essential to establish standardized clinical guidelines.Keywords
This publication has 20 references indexed in Scilit:
- ADHD in females: Survey findings on symptoms across hormonal life stagesJournal of Psychiatric Research, 2025
- Examining the Link Between ADHD Symptoms and Menopausal ExperiencesJournal of Attention Disorders, 2025
- ADHD and Sex Hormones in Females: A Systematic ReviewJournal of Attention Disorders, 2025
- Perceived associations between the menstrual cycle and Attention Deficit Hyperactivity Disorder (ADHD): A qualitative interview study exploring lived experiencesSexual & Reproductive Healthcare, 2024
- Attention-deficit/hyperactivity disorder and the menstrual cycle: Theory and evidenceHormones and Behavior, 2023
- Prevalence of hormone-related mood disorder symptoms in women with ADHDJournal of Psychiatric Research, 2021
- Reproductive steroids and ADHD symptoms across the menstrual cyclePsychoneuroendocrinology, 2018
- Lisdexamfetamine Effects on Executive Activation and Neurochemistry in Menopausal Women with Executive Function DifficultiesNeuropsychopharmacology, 2016
- New onset executive function difficulties at menopause: a possible role for lisdexamfetaminePsychopharmacology, 2015
- Potential hormonal mechanisms of Attention-Deficit/Hyperactivity Disorder and Major Depressive Disorder: A new perspectiveHormones and Behavior, 2009